<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04119765</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0408</org_study_id>
    <nct_id>NCT04119765</nct_id>
  </id_info>
  <brief_title>Plasma Oxalate in Patient With Short Bowel</brief_title>
  <acronym>OXAGO</acronym>
  <official_title>Plasma Oxalate in Patient With Short Bowel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperoxaluria due to fat malabsorption is seen in patients suffering from short bowel and can
      lead to stones and nephrocalcinosis. Not all patients are prone to these renal complications.
      only urinary oxaluria is measured in practice. Plasma oxalate shouldn't increase
      theoretically in these patients. However recent report showed an increase of plasma oxalate
      in patient with enteric hyperoxaluria. The aim of this study is to assess the plasma oxalate
      distribution in this specific population to have a new tool to predict renal complication of
      these patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma oxalate rate (oxalemia)</measure>
    <time_frame>at inclusion</time_frame>
    <description>this sample measures the plasma oxalate rate</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Short Bowel Syndrome</condition>
  <condition>Hyperoxaluria</condition>
  <condition>Hyperoxalemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>blood sampling will be used to perform oxalemia and FGF23 quantitative analysis</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Urine sampling</intervention_name>
    <description>urine sampling will be used to measure glycolate urinary rate (glycolaturia) and to perform urinary inflammation markers quantitative analysis</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulse Wave Velocity (PWV) measurement</intervention_name>
    <description>PWV will be measured thank to the Complior® device</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>central pressure measurement</intervention_name>
    <description>central pressure will be measured thank to the Complior® device</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        type II short bowel patient
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Type II short bowel for more than 6 months

          -  Affiliated to a social health care

        Exclusion Criteria:

          -  Primary hyperoxaluria

          -  Other type of short bowel than type II

          -  Minor patient or major patient protected by the law
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandrine Lemoine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandrine Lemoine, MD</last_name>
    <phone>0472110244</phone>
    <email>Sandrine.lemoine01@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nephrology Department, Edouard Herriot Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine Lemoine</last_name>
      <phone>0472110244</phone>
      <email>Sandrine.lemoine01@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Sandrine Lemoine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 7, 2019</study_first_submitted>
  <study_first_submitted_qc>October 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2019</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Short Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

